Cargando…
Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia
Vancomycin (VAN) and daptomycin (DAP) are approved as a monotherapy for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. A regimen of daptomycin plus ceftaroline (DAP+CPT) has shown promise in published case series of MRSA salvage therapy, but no comparative data exist to compare up-fr...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6496065/ https://www.ncbi.nlm.nih.gov/pubmed/30858203 http://dx.doi.org/10.1128/AAC.02483-18 |
_version_ | 1783415382247211008 |
---|---|
author | Geriak, Matthew Haddad, Fadi Rizvi, Khulood Rose, Warren Kullar, Ravina LaPlante, Kerry Yu, Marie Vasina, Logan Ouellette, Krista Zervos, Marcus Nizet, Victor Sakoulas, George |
author_facet | Geriak, Matthew Haddad, Fadi Rizvi, Khulood Rose, Warren Kullar, Ravina LaPlante, Kerry Yu, Marie Vasina, Logan Ouellette, Krista Zervos, Marcus Nizet, Victor Sakoulas, George |
author_sort | Geriak, Matthew |
collection | PubMed |
description | Vancomycin (VAN) and daptomycin (DAP) are approved as a monotherapy for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. A regimen of daptomycin plus ceftaroline (DAP+CPT) has shown promise in published case series of MRSA salvage therapy, but no comparative data exist to compare up-front DAP+CPT head-to-head therapy versus standard monotherapy as an initial treatment. In a pilot study, we evaluated 40 adult patients who were randomized to receive 6 to 8 mg/kg of body weight per day of DAP and 600 mg intravenous (i.v.) CPT every 8 h (q8h) (n = 17) or standard monotherapy (n = 23) with vancomycin (VAN; dosed to achieve serum trough concentrations of 15 to 20 mg/liter; n = 21) or 6 to 8 mg/kg/day DAP (n = 2). Serum drawn on the first day of bacteremia was sent to a reference laboratory post hoc for measurement of interleukin-10 (IL-10) concentrations and correlation to in-hospital mortality. Sources of bacteremia, median Pitt bacteremia scores, Charlson comorbidity indices, and median IL-10 serum concentrations were similar in both groups. Although the study was initially designed to examine bacteremia duration, we observed an unanticipated in-hospital mortality difference of 0% (0/17) for combination therapy and 26% (6/23) for monotherapy (P = 0.029), causing us to halt the study. Among patients with an IL-10 concentration of >5 pg/ml, 0% (0/14) died in the DAP+CPT group versus 26% (5/19) in the monotherapy group (P = 0.057). Here, we share the full results of this preliminary (but aborted) assessment of early DAP+CPT therapy versus standard monotherapy in MRSA bacteremia, hoping to encourage a more definitive clinical trial of its potential benefits against this leading cause of infection-associated mortality. (The clinical study discussed in this paper has been registered at ClinicalTrials.gov under identifier NCT02660346.) |
format | Online Article Text |
id | pubmed-6496065 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | American Society for Microbiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-64960652019-10-25 Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia Geriak, Matthew Haddad, Fadi Rizvi, Khulood Rose, Warren Kullar, Ravina LaPlante, Kerry Yu, Marie Vasina, Logan Ouellette, Krista Zervos, Marcus Nizet, Victor Sakoulas, George Antimicrob Agents Chemother Clinical Therapeutics Vancomycin (VAN) and daptomycin (DAP) are approved as a monotherapy for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. A regimen of daptomycin plus ceftaroline (DAP+CPT) has shown promise in published case series of MRSA salvage therapy, but no comparative data exist to compare up-front DAP+CPT head-to-head therapy versus standard monotherapy as an initial treatment. In a pilot study, we evaluated 40 adult patients who were randomized to receive 6 to 8 mg/kg of body weight per day of DAP and 600 mg intravenous (i.v.) CPT every 8 h (q8h) (n = 17) or standard monotherapy (n = 23) with vancomycin (VAN; dosed to achieve serum trough concentrations of 15 to 20 mg/liter; n = 21) or 6 to 8 mg/kg/day DAP (n = 2). Serum drawn on the first day of bacteremia was sent to a reference laboratory post hoc for measurement of interleukin-10 (IL-10) concentrations and correlation to in-hospital mortality. Sources of bacteremia, median Pitt bacteremia scores, Charlson comorbidity indices, and median IL-10 serum concentrations were similar in both groups. Although the study was initially designed to examine bacteremia duration, we observed an unanticipated in-hospital mortality difference of 0% (0/17) for combination therapy and 26% (6/23) for monotherapy (P = 0.029), causing us to halt the study. Among patients with an IL-10 concentration of >5 pg/ml, 0% (0/14) died in the DAP+CPT group versus 26% (5/19) in the monotherapy group (P = 0.057). Here, we share the full results of this preliminary (but aborted) assessment of early DAP+CPT therapy versus standard monotherapy in MRSA bacteremia, hoping to encourage a more definitive clinical trial of its potential benefits against this leading cause of infection-associated mortality. (The clinical study discussed in this paper has been registered at ClinicalTrials.gov under identifier NCT02660346.) American Society for Microbiology 2019-04-25 /pmc/articles/PMC6496065/ /pubmed/30858203 http://dx.doi.org/10.1128/AAC.02483-18 Text en Copyright © 2019 Geriak et al. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Clinical Therapeutics Geriak, Matthew Haddad, Fadi Rizvi, Khulood Rose, Warren Kullar, Ravina LaPlante, Kerry Yu, Marie Vasina, Logan Ouellette, Krista Zervos, Marcus Nizet, Victor Sakoulas, George Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia |
title | Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia |
title_full | Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia |
title_fullStr | Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia |
title_full_unstemmed | Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia |
title_short | Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia |
title_sort | clinical data on daptomycin plus ceftaroline versus standard of care monotherapy in the treatment of methicillin-resistant staphylococcus aureus bacteremia |
topic | Clinical Therapeutics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6496065/ https://www.ncbi.nlm.nih.gov/pubmed/30858203 http://dx.doi.org/10.1128/AAC.02483-18 |
work_keys_str_mv | AT geriakmatthew clinicaldataondaptomycinplusceftarolineversusstandardofcaremonotherapyinthetreatmentofmethicillinresistantstaphylococcusaureusbacteremia AT haddadfadi clinicaldataondaptomycinplusceftarolineversusstandardofcaremonotherapyinthetreatmentofmethicillinresistantstaphylococcusaureusbacteremia AT rizvikhulood clinicaldataondaptomycinplusceftarolineversusstandardofcaremonotherapyinthetreatmentofmethicillinresistantstaphylococcusaureusbacteremia AT rosewarren clinicaldataondaptomycinplusceftarolineversusstandardofcaremonotherapyinthetreatmentofmethicillinresistantstaphylococcusaureusbacteremia AT kullarravina clinicaldataondaptomycinplusceftarolineversusstandardofcaremonotherapyinthetreatmentofmethicillinresistantstaphylococcusaureusbacteremia AT laplantekerry clinicaldataondaptomycinplusceftarolineversusstandardofcaremonotherapyinthetreatmentofmethicillinresistantstaphylococcusaureusbacteremia AT yumarie clinicaldataondaptomycinplusceftarolineversusstandardofcaremonotherapyinthetreatmentofmethicillinresistantstaphylococcusaureusbacteremia AT vasinalogan clinicaldataondaptomycinplusceftarolineversusstandardofcaremonotherapyinthetreatmentofmethicillinresistantstaphylococcusaureusbacteremia AT ouellettekrista clinicaldataondaptomycinplusceftarolineversusstandardofcaremonotherapyinthetreatmentofmethicillinresistantstaphylococcusaureusbacteremia AT zervosmarcus clinicaldataondaptomycinplusceftarolineversusstandardofcaremonotherapyinthetreatmentofmethicillinresistantstaphylococcusaureusbacteremia AT nizetvictor clinicaldataondaptomycinplusceftarolineversusstandardofcaremonotherapyinthetreatmentofmethicillinresistantstaphylococcusaureusbacteremia AT sakoulasgeorge clinicaldataondaptomycinplusceftarolineversusstandardofcaremonotherapyinthetreatmentofmethicillinresistantstaphylococcusaureusbacteremia |